AstraZeneca PLC (AZNCF)
| Previous Close | 127.39 |
| Open | 131.66 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 131.50 - 131.66 |
| 52 Week Range | 105.26 - 143.90 |
| Volume | |
| Avg. Volume | 2,816 |
| Market Cap | 205.234B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.72 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.84 (2.23%) |
| Ex-Dividend Date | Aug 11, 2022 |
| 1y Target Est | N/A |
- Zacks
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
- Reuters
UPDATE 1-AstraZeneca-Daiichi's breast cancer drug improves survival in study
AstraZeneca said on Monday its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients, boosting prospects of more regulatory approvals. Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer, the company said. The HER2 protein contributes to the growth and spread of breast cancer.
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
WILMINGTON, Del., August 12, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.
